The present exploratory study demonstrated that the combination of clinical (age, ALT, HOMA-IR, and sarcopenia), metabolomic (sphingolipids, glycerophospholipids, and tyrosine), and genomic (PNPLA3 genotype) biomarkers accurately predicted a higher FAST score (>0.35). This evidence concerns the gene PNPLA3 and sarcopenia.